12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
The Latest Breaking News from Caladrius Biosciences
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Avalo Therapeutics (NASDAQ:AVTX) has dosed the first patient in the pivotal LADDER trial to assess the efficacy and safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II) ER). Avalo shares traded in a range of $3.5 to $3.91 on a day volume of 33.54 thousand shares,…
Benzinga ·
Caladrius Biosciences Stops Enrollment In Mid-Stage Heart Disease Study
Caladrius Biosciences Inc (NASDAQ:CLBS) suspended patient enrollment in its Phase 2b FREEDOM Trial of Xowna for coronary microvascular dysfunction (CMD). As previously communicated, the pandemic impacted the enrollment in the FREEDOM Trial coupled with supply chain issues making enrollment much slower and challenging to accelerate. The FREEDOM trial enrolled approximately one-third of the…
Benzinga ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Coverage From
Benzinga
Organisations
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Topics
Read news from The Economist, FT, and more,
with one subscription
with one subscription
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
